The CEO of Dante Labs, Andrea Riposati, is one of the most well-known and respected figures in the pharmaceutical industry. He has presided over unprecedented growth in the company’s history while innovating to keep Dante Labs at the cutting edge of research. With over 20 years in leadership positions at some of today’s most innovative biotech companies, he knows first-hand how to create and execute strategies that deliver measurable results.
- About Dante Labs
Dante Labs is a specialty pharmaceutical company that discovers and develops novel therapeutic candidates for treating autoimmune diseases. The Company has developed several lead programs in these high-value areas and has signed several agreements. The Company’s pipeline consists of compounds potentially valuable in treating cancer, autoimmune disease (including psoriasis, multiple sclerosis and others), and infectious diseases.
- Andrea Riposati’s Mission for Dante Labs
Dante is committed to developing and commercializing innovative therapies for autoimmune diseases and immunology disorders. The Company’s long-term goals include expanding its pipeline and acquiring additional assets to accelerate Dante’s competitive position in the market. Dante’s management philosophy is to be highly selective in developing assets, retaining them through a strong management team and resources, and persevering over a significant period to complete the required clinical trials.
- The Inspiration Behind Dante Labs
From working on this project and three subsequent projects, Dante identified the target molecule to be produced by inducing cells to secrete high concentrations of interferon beta. This molecule has been approved by the U.S. Food and Drug Administration (FDA) for treating relapsing forms of Multiple Sclerosis.
Andrea Riposati is one of the most well-known and respected figures in the pharmaceutical industry. He is a pioneer in the biotechnology industry, having worked on some of the most innovative drug research projects of this decade.